THERAVANCE BIOPHARMA, INC. (TBPH) Net margin 2016–2025
THERAVANCE BIOPHARMA, INC. (TBPH) net profit margin by fiscal year — reported net income divided by reported revenue.
98.5%FY2025 · since FY2016: -391.9% → 98.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 98.5% | +186.2 pp |
| FY2024 | -87.6% | +8.5 pp |
| FY2023 | -96.1% | -1794.7 pp |
| FY2022 | 1698.5% | +2059.1 pp |
| FY2021 | -360.6% | +26.3 pp |
| FY2020 | -386.9% | -64.8 pp |
| FY2019 | -322.1% | +34.9 pp |
| FY2018 | -357.0% | +1498.0 pp |
| FY2017 | -1855.0% | -1463.0 pp |
| FY2016 | -391.9% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice